Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease
Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease
复制标题
DOI：
10.1007/s10557-008-6148-1
复制
发表时间：
2009-02-01
影响因子：
3.4
通讯作者：
Rosenson, Robert S.
中科院分区：
文献类型：
--
作者：
Rosenson, Robert S.
即使在接受循证医学标准治疗的患者中，心血管事件复发的风险也很高，这促使人们研究旨在降低动脉粥样硬化负荷和改善易损动脉粥样硬化斑块稳定性的新方法，以进一步降低心血管事件的风险[1]。磷脂酶A（2）超家族的成员参与脂蛋白的修饰、滞留和氧化，并激活血管和全身炎症反应，因此可作为治疗的潜在靶点，以减少心血管事件[2，3]。本文将综述选择性磷脂酶A2抑制剂的实验和人体研究，并讨论这些药物在减少心血管事件中的未来作用。本文将对分泌型磷脂酶A（2）（sPLA（2））和脂蛋白相关磷脂酶A（2）（Lp-PLA（2））调节的特异性脂蛋白和炎症途径进行简要综述，以促进对其作为血管特异性治疗剂的潜在作用的理解。
The high risk of recurrent cardiovascular events even among those receiving standard-of-care therapies established on evidence-based medicine has prompted investigations into novel approaches directed at reducing atherosclerotic burden and improving stability of vulnerable atherosclerotic plaques in an effort to further reduce the risk of cardiovascular events [1]. Members of the phospholipase A(2) superfamily of enzymes serve as potential targets of therapy to reduce cardiovascular events as they are involved in lipoprotein modification, retention and oxidation; and activation of vascular and systemic inflammatory responses [2, 3].This article will review experimental and human studies with selective phospholipase A2 inhibitors, and discuss the future role for these agents in reducing cardiovascular events. A brief review of specific lipoprotein and inflammatory pathways modulated by secretory phospholipase A(2) (sPLA(2)) enzymes and lipoprotein-associated phospholipase A(2) ( Lp-PLA(2)) will be discussed to foster an understanding regarding their potential role as vascular-specific therapeutic agents.